Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.50 (-3.51%)
Spread: 0.50 (3.704%)
Open: 14.25
High: 14.00
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Top Level Domain, Transense, SkyePharma

Wed, 11th Apr 2012 09:46

Top Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry operator of a new top level domain for London. If successful, Minds and Machines will provide the registry services for the dot London domain on behalf of DLD. The contract is for a seven year period, with a three-year renewal period. Transense Technology has announced that it now has confirmed orders of $550,000 after its trading division, IntelliSAW, satisfied the conditions of a previous $275,000 order and received a second order of the same value. Under the second order, the IntelliSAW system will be deployed in Asia to provide performance data to enhance the robustness of the power grid. Significantly, industry experts have estimated that the market opportunity for sensors in Smart Grid applications to reach $85.5bn by 2014, the company said. Drug developer SkyePharma has signed a second agreement to conduct a feasibility study with RespiVert, a small molecule drug discovery company owned by Janssen Biotech. The study will develop a dry power dosage form for a RespiVert compound, designed to treat patients with severe, chronic respiratory diseases such as asthma. "We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases," the firm said. Angle, a technology commercialisation company, has announced that the clinical trial for Novocellus' IVF embryo viability product, EmbryoSure, has now begun. Novocellus is 92% owned by Angle. The firm has received approval from the Medicines and Healthcare products Regulatory Agency for the trial, and patient recruitment will begin this week. Four IVF clinics are paticipating in the trial with completion expected mid 2013. If successful, product launch is expected about a year later. Music Festivals, has announced that songwriter and performer Leonard Cohen will be joining the line up at a new event to be produced by the Group called 'A Day at Hop Farm' to be held in September of this year at the same place as the Hop Farm Festival in Kent. "To get the opportunity to bring Leonard Cohen to the UK for his only appearance this year is a fantastic and humbling achievement. He is one of the undisputed forefathers of modern folk music and has honed his craft for nearly half a century. We are delighted he's decided to perform for us for what will be a truly memorable experience," the firm said. UK gun manufactuter Manroy has won two new orders for its general purpose machine gun, worth a total of £0.4m, from two overseas customers. The firm said that although they were relatively small in value they were significant in terms of their strategic impact as it "confirms new and important export regions for the group". NR
More News
5 Jun 2024 16:32

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Jun 2024 10:08

Angle unveils plans to raise more than £10m

(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

Read more
16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.